๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical pharmacology of 4-demethoxydaunorubicin (DMDR)

โœ Scribed by Katherine Lu; Niramol Savaraj; John Kavanagh; Lynn G. Feun; Michael Burgess; Gerald P. Bodey; Ti Li Loo

Publisher
Springer
Year
1986
Tongue
English
Weight
527 KB
Volume
17
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase II trial of oral 4โ€ฒ demethoxydau
A phase II trial of oral 4โ€ฒ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer
โœ P. Presgrave; R. Woods; R. Kefford; D. Bell; D. Raghavan; J. Levi ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 216 KB

4' Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m 2 and 40 mg/m 2 respectively at 28 day intervals. All 22 pat

Phase II clinical and pharmacological st
Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer
โœ Robert Milroy; Jeffrey Cummings; Stanley B. Kaye; Stephen W. Banham ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer ๐ŸŒ English โš– 298 KB

4-Demethoxydaunorubicin (4-DMDNR) is an oral anthracycline with antitumour activity demonstrated in a number of clinical studies. We have assessed the usefulness of 4-DMDNR in 16 patients with advanced small cell lung cancer, none of whom had received previous chemotherapy. There were no complete or